- Bio-Techne (TECH, Financial) to participate in 2025 AACR Annual Meeting, showcasing advanced cancer research tools.
- The company's exhibit will feature cutting-edge solutions including proteins, antibodies, and spatial multiomics applications.
- Bio-Techne will present 10 research posters on various topics, enhancing oncology research and diagnostics.
Bio-Techne Corporation (NASDAQ: TECH) has announced its participation in the 2025 American Association for Cancer Research (AACR) Annual Meeting, which will take place from April 25-30 at the McCormick Place Convention Center in Chicago, IL. Recognized as a pivotal event in the cancer research community, AACR convenes global experts to share groundbreaking discoveries and innovations in cancer science and medicine.
At booth #3049, Bio-Techne will display its extensive oncology research portfolio. This includes high-performance proteins, antibodies, cell culture reagents, immunoassays, and automated proteomic analysis platforms, as well as spatial multiomic solutions designed to accelerate advancements in immune cell therapy development and support next-generation diagnostic tools. The Advanced Cell Diagnostics (ACD) brand will highlight its RNAscope™ spatial portfolio and host an evening reception on April 27th in collaboration with Leica Biosystems and Indica Labs.
Meanwhile, at booth #3249, Lunaphore, another Bio-Techne brand, will showcase its comprehensive spatial biology solutions. This includes the launch of a fully-automated, same-section multiomics application for fixed-frozen tissue. An exclusive dinner reception on April 28th will offer a unique platform for connecting with industry leaders and exploring Lunaphore's forthcoming tools, such as the HORIZON™ image analysis software.
In addition to these exhibits, Bio-Techne will present ten scientific posters addressing topics such as protein quantitation, biomarker evaluation, and spatial multiomics analysis in cancer research. These presentations aim to further advance understanding and innovation within oncology research, contributing significantly to the field of precision medicine and the development of next-generation cancer therapies.
Bio-Techne's President and CEO, Kim Kelderman, emphasized the company's commitment to equipping scientists with cutting-edge tools that foster discovery and innovation in cancer research, ultimately shaping the future of precision medicine. For more information on Bio-Techne's involvement at AACR 2025, interested parties can visit their website.
